Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC) and NonAlcoholic SteatoHepatitis (NASH). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800
investors@cymabay.com

Recent News

12Mar

CymaBay Therapeutics to Present at Upcoming Investor Conferences in March

11Mar

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

6Mar

CymaBay Announces Pricing of Public Offering of Common Stock

Upcoming Event

Mar 20 2019 8:35 am ET

Oppenheimer 29th Annual Healthcare Conference

March 20, 2019 at 8:35 am ET

Q4 2018 Quarterly Results